Hirt Carsten, Schüler Frank, Dölken Gottfried
Department of Hematology and Oncology, University Medical Center, Ernst-Moritz-Arndt-University, Sauerbruchstrasse, D-17487 Greifswald, Germany.
Semin Cancer Biol. 2003 Jun;13(3):223-31. doi: 10.1016/s1044-579x(03)00017-8.
The t(14;18)-translocation can be detected by PCR analysis in more than 90% of cytogenetically t(14;18)-positive follicular lymphomas (FLs), thus providing an easily accessible marker for molecular disease monitoring. Various technical aspects of the detection of residual lymphoma cells as well as the prognostic and clinical significance of the detection of minimal residual disease (MRD) after radiotherapy, chemotherapy and therapy with the monoclonal antibody rituximab are discussed. Up to now the comparability of the different studies investigating minimal residual disease in follicular lymphoma patients is hampered by the use of a variety of PCR techniques. A more standardized quantitative approach based on the real-time PCR technique will provide a powerful tool for the evaluation and optimization of therapy for each individual patient.
通过聚合酶链反应（PCR）分析，在超过90%细胞遗传学检测显示t(14;18)阳性的滤泡性淋巴瘤（FL）中可检测到t(14;18)易位，从而为分子疾病监测提供了一个易于获取的标志物。本文讨论了检测残留淋巴瘤细胞的各种技术方面，以及放疗、化疗和单克隆抗体利妥昔单抗治疗后检测微小残留病（MRD）的预后和临床意义。到目前为止，由于使用了多种PCR技术，不同研究中对滤泡性淋巴瘤患者微小残留病的研究可比性受到影响。基于实时PCR技术的更标准化定量方法将为评估和优化每位患者的治疗提供有力工具。
